MarketPeel
EG

Erick Gamelin

ACRV
CHIEF DEVELOPMENT OFFICER · ACRIVON THERAPEUTICS, INC. · CIK 0001950551
FILING MIX · LIFETIME33%/67%
BUYS
6
SELLS
12
TOTAL VALUE
$24.9K
COMPANIES
1
ACTIVE SINCE
Nov 2022
HOLDINGS NOW
52,592
AVG SELL PX
$4.13
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
No backtest data available for Erick Gamelin. Backtests are computed for purchase (P) and sale (S) transactions with resolvable price history.
Holdings over time
ACRV · 52,592 shares · as of Aug 18, 2026
023,73747,47371,21094,9462023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 6 buys / 12 sellsCOVERAGE · 16 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
400$2.01$80452,592Aug 18, 2026Aug 20, 2026View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
38,58452,992May 18, 2026May 20, 2026View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
404$1.92$77614,408May 14, 2026May 18, 2026View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
94,94694,946Mar 1, 2026Mar 3, 2026View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
471$1.63$76814,812Feb 14, 2026Feb 18, 2026View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
403$2.24$90315,283Nov 14, 2025Nov 18, 2025View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
403$1.39$56015,686Aug 14, 2025Aug 18, 2025View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
403$1.14$45916,089May 14, 2025May 16, 2025View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
78,07878,078Mar 1, 2025Mar 4, 2025View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
469$5.42$2.5K16,492Feb 14, 2025Feb 19, 2025View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
402$7.92$3.2K16,961Nov 14, 2024Nov 18, 2024View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
402$7.02$2.8K17,363Aug 14, 2024Aug 16, 2024View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
402$8.36$3.4K17,765May 14, 2024May 16, 2024View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,04545,045Mar 1, 2024Nov 27, 2024View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Development Officer
468$3.40$1.6K18,167Feb 14, 2024Feb 16, 2024View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Medical Officer
1,395$5.08$7.1K18,635Nov 14, 2023Nov 16, 2023View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,03020,030Nov 14, 2022Nov 16, 2022View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,09060,090Nov 14, 2022Nov 16, 2022View →
Other insiders · ACRV
Loading peer insiders…
About this filer
CIK 0001950551
ROLE
Chief Development Officer
PRIMARY
ACRV
COMPANIES
1
ACTIVE SINCE
Nov 2022
MARKETPEEL · /INSIDER/0001950551DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback